ARL2BP

Across TCGA pan-cancer cohorts, ARL2BP mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ARL2BP data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ARL2BP mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARL2BP expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where ARL2BP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.649	0.871	<.001	57	view →
LSCC	DFS	Tertile	II,III,IV	0.677	0.896	.005	22	view →
LUAD	OS	Median	II,III,IV	0.831	0.459	.002	7	view →
CCRCC	DFS	Tertile	III,IV	0.904	0.066	.024	4	view →
HNSC	DFS	Median	IV	0.579	0.743	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ARL2BP–PDAC (DFS)

Open the PDAC breakdown →